Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase  3 Trials

ConclusionEfficacy and safety of ubrogepant for the acute treatment of migraine were similar between participants with or without prior or current use of concomitant preventive medication.Trial RegistrationClinicalTrials.gov identifiers: NCT02828020 (ACHIEVE  I), NCT02867709 (ACHIEVE II), and NCT02873221 (long-term safety trial).
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research